Syneos Health Inc (NASDAQ:SYNH) – Research analysts at William Blair lowered their FY2019 earnings per share (EPS) estimates for Syneos Health in a note issued to investors on Tuesday, January 8th. William Blair analyst J. Kreger now expects that the company will post earnings per share of $2.70 for the year, down from their prior forecast of $2.79. William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for Syneos Health’s FY2020 earnings at $3.09 EPS and FY2021 earnings at $3.51 EPS.

Syneos Health (NASDAQ:SYNH) last posted its earnings results on Tuesday, November 6th. The company reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.17. Syneos Health had a positive return on equity of 8.67% and a negative net margin of 0.84%. The business had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Syneos Health’s revenue was up 88.3% on a year-over-year basis.

SYNH has been the topic of a number of other research reports. Evercore ISI began coverage on Syneos Health in a research report on Thursday, October 4th. They set an “outperform” rating and a $58.00 price target on the stock. UBS Group assumed coverage on Syneos Health in a report on Tuesday, October 9th. They issued a “buy” rating and a $60.00 target price for the company. SunTrust Banks cut their price target on Syneos Health to $55.00 and set a “buy” rating for the company in a report on Wednesday, December 19th. Zacks Investment Research upgraded Syneos Health from a “hold” rating to a “buy” rating and set a $49.00 price objective on the stock in a research report on Tuesday, December 18th. Finally, ValuEngine upgraded Syneos Health from a “sell” rating to a “hold” rating in a research report on Saturday, September 22nd. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Syneos Health presently has an average rating of “Buy” and a consensus price target of $53.44.

Syneos Health stock opened at $47.57 on Friday. Syneos Health has a one year low of $31.10 and a one year high of $53.95. The company has a current ratio of 0.97, a quick ratio of 0.97 and a debt-to-equity ratio of 0.99. The company has a market capitalization of $4.68 billion, a P/E ratio of 24.52, a P/E/G ratio of 1.28 and a beta of 1.28.

In other Syneos Health news, CFO Jason M. Meggs purchased 3,650 shares of the firm’s stock in a transaction dated Monday, December 17th. The stock was acquired at an average cost of $41.25 per share, with a total value of $150,562.50. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, General Counsel Jonathan Olefson purchased 750 shares of the firm’s stock in a transaction dated Monday, December 17th. The stock was acquired at an average cost of $41.27 per share, with a total value of $30,952.50. The disclosure for this purchase can be found here. 0.57% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. First Hawaiian Bank lifted its stake in Syneos Health by 2.9% in the fourth quarter. First Hawaiian Bank now owns 12,562 shares of the company’s stock valued at $494,000 after acquiring an additional 350 shares during the last quarter. Vanguard Group Inc grew its holdings in shares of Syneos Health by 9.9% in the 3rd quarter. Vanguard Group Inc now owns 6,914,223 shares of the company’s stock worth $356,429,000 after purchasing an additional 624,991 shares during the last quarter. Federated Investors Inc. PA grew its holdings in shares of Syneos Health by 3.6% in the 3rd quarter. Federated Investors Inc. PA now owns 24,009 shares of the company’s stock worth $1,238,000 after purchasing an additional 838 shares during the last quarter. Marshall Wace North America L.P. bought a new stake in shares of Syneos Health in the 3rd quarter worth about $17,537,000. Finally, Marshall Wace LLP acquired a new position in Syneos Health during the 3rd quarter worth about $1,823,000.

About Syneos Health

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Read More: What is Considered a Good Return on Equity (ROE)?

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.